Fig. 7

2-BP/CPT-PLNs improved systemic antitumor efficacy and prolonged the survival of B16-F10 tumor-bearing mice. A Schematic illustration of the treatment regimen for the subcutaneous B16-F10 tumor model. B-H Tumor growth files and survival files of tumor-bearing mice after the above programmatic treatments (n = 8). Data were represented as mean ± SD